title: The role of complement, platelet-activating factor and leukotriene B4 in a reversed passive Arthus reaction.
abstract: 1. The mechanisms underlying oedema formation induced in a reversed passive Arthus (RPA) reaction and, for comparison, in response to zymosan in rabbit skin were investigated. 2. Oedema formation at skin sites was quantified by the accumulation of intravenously-injected 125I-labelled human serum albumin. 3. Recombinant soluble complement receptor type 1 (sCR1), administered locally in rabbit skin, suppressed oedema formation induced in the RPA reaction and by zymosan. 4. The platelet-activating factor (PAF) antagonists, WEB 2086 and PF10040 administered locally, inhibited oedema formation induced in the RPA reaction and by PAF but not by zymosan. 5. A locally administered leukotriene B4 (LTB4) antagonist, LY-255283, inhibited oedema formation induced by LTB4 but did not inhibit oedema responses to PAF, zymosan or the RPA reaction. 6. The results demonstrate a role for complement in oedema formation in both the RPA reaction and in response to zymosan. An important contribution by PAF is indicated in the RPA reaction but not in response to zymosan whereas no evidence was obtained to suggest a role for LTB4 in either inflammatory response.
authors.affiliation: Department of Applied Pharmacology, National Heart & Lung Institute, London.
authors.forename: A G
authors.initials: AG
authors.lastname: Rossi
authors.forename: K E
authors.initials: KE
authors.lastname: Norman
authors.forename: D
authors.initials: D
authors.lastname: Donigi-Gale
authors.forename: T S
authors.initials: TS
authors.lastname: Shoupe
authors.forename: R
authors.initials: R
authors.lastname: Edwards
authors.forename: T J
authors.initials: TJ
authors.lastname: Williams
mesh_terms: D000818:Animals; D001183:Arthus Reaction / Q000209:etiology*; D001381:Azepines / Q000494:pharmacology; D003165:Complement System Proteins / Q000502:physiology*; D004487:Edema / Q000209:etiology; D007546:Isoquinolines / Q000494:pharmacology; D007975:Leukotriene B4 / Q000037:antagonists & inhibitors / Q000502:physiology*; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors / Q000502:physiology*; D011817:Rabbits; D011863:Radioimmunoassay; D011951:Receptors, Complement; D013777:Tetrazoles / Q000494:pharmacology; D014230:Triazoles / Q000494:pharmacology; D015054:Zymosan / Q000494:pharmacology
chemical_list: D001381:Azepines; D007546:Isoquinolines; D010972:Platelet Activating Factor; D011951:Receptors, Complement; D013777:Tetrazoles; D014230:Triazoles; C052518:WEB 2086; C077682:PF 10040; D007975:Leukotriene B4; D003165:Complement System Proteins; D015054:Zymosan; C063823:LY 255283